deltatrials

Respiratory syncytial virus infections Trials in Miami, United States

Conditions / Respiratory syncytial virus infections / Miami, United States

Respiratory syncytial virus infections has been the subject of sustained clinical investigation across multiple research sites.

17 total trials for this combination

Showing top 10 of 17 trials

Trials

NCT ID Title Status Phase
NCT03379675 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus COMPLETED PHASE2
NCT00384462 Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants COMPLETED
NCT04886596 Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above COMPLETED PHASE3
NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children COMPLETED PHASE3
NCT02325791 Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants COMPLETED PHASE3
NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers TERMINATED PHASE3
NCT03979313 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) COMPLETED PHASE3
NCT05559476 A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above COMPLETED PHASE3
NCT05238025 MVA-BN-RSV Vaccine Trial TERMINATED PHASE3
NCT06534892 An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study ACTIVE_NOT_RECRUITING PHASE3

Related Pages